Compare DRD & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | TRVI |
|---|---|---|
| Founded | 1895 | 2011 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2002 | 2019 |
| Metric | DRD | TRVI |
|---|---|---|
| Price | $26.72 | $16.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $32.63 | $21.55 |
| AVG Volume (30 Days) | 281.4K | ★ 1.3M |
| Earning Date | 08-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.23 | N/A |
| Revenue Next Year | $30.12 | N/A |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.47 | $7.65 |
| 52 Week High | $39.37 | $20.22 |
| Indicator | DRD | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 33.27 |
| Support Level | $26.37 | $13.08 |
| Resistance Level | $27.25 | $15.96 |
| Average True Range (ATR) | 0.84 | 0.72 |
| MACD | -0.39 | -0.17 |
| Stochastic Oscillator | 2.28 | 3.82 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.